Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline L Alvares

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Chemico-Biological Interactions|June 7, 2005
Benzene and the hemopoietic stem cellGareth J Morgan, Caroline L Alvares
Haematologica|January 26, 2006
The role of second autografts in the management of myeloma at first relapseCaroline L Alvares, Faith E Davies, Clive Horton, et al.
British Journal of Haematology|May 13, 2020
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemiaJoanna Zabkiewicz, Michelle Lazenby, Gareth Edwards, et al.
British Journal of Haematology|June 22, 2011
Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutationsCaroline L Alvares, Tino Schenk, Sanna Hulkki, et al.
Leukemia & Lymphoma|May 27, 2004
Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findingsCaroline L Alvares, Estella Matutes, Marie A Scully, et al.
Leukemia & Lymphoma|November 17, 2006
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysisPing Wu, Faith E Davies, Clive Horton, et al.
British Journal of Haematology|May 27, 2005
Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatmentsCaroline L Alvares, Faith E Davies, Clive Horton, et al.
Hematological Oncology|April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemiaBrian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Chemico-Biological Interactions|June 7, 2005
Benzene and the hemopoietic stem cellGareth J Morgan, Caroline L Alvares
Haematologica|January 26, 2006
The role of second autografts in the management of myeloma at first relapseCaroline L Alvares, Faith E Davies, Clive Horton, et al.
British Journal of Haematology|May 13, 2020
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemiaJoanna Zabkiewicz, Michelle Lazenby, Gareth Edwards, et al.
British Journal of Haematology|June 22, 2011
Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutationsCaroline L Alvares, Tino Schenk, Sanna Hulkki, et al.
Leukemia & Lymphoma|May 27, 2004
Isolated bone marrow involvement in diffuse large B cell lymphoma: a report of three cases with review of morphological, immunophenotypic and cytogenetic findingsCaroline L Alvares, Estella Matutes, Marie A Scully, et al.
Leukemia & Lymphoma|November 17, 2006
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysisPing Wu, Faith E Davies, Clive Horton, et al.
British Journal of Haematology|May 27, 2005
Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatmentsCaroline L Alvares, Faith E Davies, Clive Horton, et al.
Hematological Oncology|April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemiaBrian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Pageof 1